Overview

Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Status:
Active, not recruiting

Trial end date:
2021-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.

Phase:

Phase 2

Details

Lead Sponsor:

CytoDyn, Inc.

Treatments:

Leronlimab